The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.
The company has multiple companion diagnostics partnerships in the works, with new tests on the way in 2020, and new plans for next-generation sequencing.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
Takeda said that the tool evaluates risk for developing complications associated with Crohn's disease and helps support personalized clinical decision-making.
The sites include Massachusetts General Hospital, Northwestern Medicine, Struthers Parkinson's Center, UC San Diego, and the Perelman School of Medicine.
Proscia said that its partnership with Johns Hopkins, which aims to accelerate research breakthroughs and improve patient outcomes, is one among a number of its recent pathology-related engagements.
Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.
The firms noted that QuantuMDx’s Capture-XT technology will enable downstream drug-susceptibility analysis, PCR, NGS, and, with this collaboration, nanopore detection.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
Inspirata said that the partners will combine their digital pathology products to address challenges with traditional pathology testing for H. Pylori.